Provided by Tiger Trade Technology Pte. Ltd.

Xeris Pharmaceuticals Inc

10.51
+0.32003.14%
Volume:1.18M
Turnover:12.25M
Market Cap:1.92B
PE:-103.04
High:10.54
Open:10.15
Low:10.08
Close:10.19
52wk High:11.33
52wk Low:5.25
Shares:182.32M
Float Shares:172.57M
Volume Ratio:0.68
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1020
EPS(LYR):0.0032
ROE:-617.16%
ROA:6.13%
PB:-196.85
PE(LYR):3,277.21

Loading ...

Oct 01, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 28, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 09, 2026

Major Issues Report

Form 8-K - Current report
Aug 12, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 06, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 06, 2026

Major Issues Report

Form 8-K - Current report
Jul 31, 2026

Beneficial Ownership Change

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Jul 17, 2026

Major Issues Report

Form 8-K - Current report
Jul 07, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 06, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 02, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 01, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 30, 2026

Major Issues Report

Form 8-K - Current report
Jun 11, 2026

Major Issues Report

Form 8-K - Current report
Jun 05, 2026

Major Issues Report

Form 8-K - Current report
Jun 04, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 04, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 04, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 04, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 07, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]